Intismeran Clears Phase 3 in Melanoma. The Numbers Still Matter
On August 19, Moderna and Merck reported the first positive Phase 3 result for an individualized neoantigen therapy and an mRNA-based cancer therapy. In the 1,137-patient INTerpath-001 trial, intismeran autogene plus pembrolizumab beat pembrolizumab alone after complete surgery for stage IIB-IV melanoma.
The combination met the primary endpoint of recurrence-free survival and the key secondary endpoint of distant metastasis-free survival. The companies called both improvements statistically significant and clinically meaningful.
What the trial tested
INTerpath-001 randomized patients 2:1. The combination arm received intismeran every three weeks for up to nine doses and pembrolizumab every six weeks for up to nine cycles; the control arm received pembrolizumab alone.
Intismeran is made from a patient’s tumor sequence. Its synthetic mRNA encodes up to 34 tumor-specific neoantigens, with the aim of teaching T cells which cancer cells to attack.
This is adjuvant treatment. The visible tumor had already been removed, so the trial tested whether treatment could delay recurrence, distant spread or death—not whether a vaccine could prevent cancer from developing in healthy people.
Why the result is a milestone
Cancer vaccines have produced encouraging small or early-stage studies before. INTerpath-001 is the first randomized Phase 3 readout to show an individualized neoantigen therapy improving outcomes, and the first positive Phase 3 result for an mRNA cancer therapy.
The result also confirms the direction of the 157-patient Phase 2b KEYNOTE-942 study. At five years, that study reported a 49% lower risk of recurrence or death and a 59% lower risk of distant metastasis or death with the combination.
What is still missing
The August 19 release gave no Phase 3 hazard ratios, absolute event rates, confidence intervals or subgroup results. Overall survival is still being followed. Safety showed no new signal, but detailed adverse-event tables have not been published.
The companies plan to present the dataset at a medical meeting and discuss filings with regulators. Intismeran remains investigational; a successful topline result is not regulatory approval.
That boundary matters. This is strong clinical validation for personalized mRNA cancer therapy, not proof that one platform works against every cancer.
References
- https://news.modernatx.com/merck-and-moderna-announce-phase-3-interpath-001-trial-of-intismeran-plus-keytruda-met-endpoints-of-rfs-and-dmfs-in-melanoma
- https://clinicaltrials.gov/study/NCT05933577
- https://www.merck.com/news/moderna-and-merck-present-5-year-data-for-intismeran-autogene-in-combination-with-keytruda-pembrolizumab-in-patients-with-high-risk-stage-iii-iv-melanoma-following-complete-resection-at-the-20/
- https://ascopubs.org/doi/10.1200/JCO-26-00835